查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994302

頭孢噻呋市場：給藥途徑、適應症、劑型、最終用戶、動物種類 - 全球市場預測 2026-2032

Ceftiofur Market by Route, Indication, Formulation, End User, Animal Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，頭孢噻呋市場價值將達到 4.7185 億美元，到 2026 年將成長至 5.0578 億美元，到 2032 年將達到 8.7282 億美元，複合年成長率為 9.18%。

主要市場統計數據
基準年 2025 4.7185億美元
預計年份：2026年 5.0578億美元
預測年份 2032 872,820,000 美元
複合年成長率 (%) 9.18%

對頭孢噻呋在現代獸醫學中的治療作用、監管現狀、合理使用預期以及相關人員的優先事項進行全面概述。

頭孢噻呋仍然是獸醫學中的重要抗生素，因其頻譜抗菌作用和在多種畜禽物種中確立的臨床效用價值而備受推崇。隨著臨床證據、獸醫標準的不斷更新以及全球對合理使用抗生素日益成長的關注，頭孢噻呋在治療通訊協定中的作用也在不斷發展。在相關人員權衡治療效益與監管和公共衛生義務的同時，負責人、農場管理者和供應鏈規劃人員必須清楚了解頭孢噻呋的臨床適應症、給藥途徑和製劑選擇。

分析了頭孢噻呋在獸藥領域的應用、供應鏈、合理使用抗生素和產品創新所發生的變革性變化。

頭孢噻呋的研發、分銷和處方環境正經歷顯著變化，其促進因素包括不斷變化的監管環境、供應鏈重組以及技術創新。日益嚴格的監管和對合理用藥的日益重視正在重塑產品標籤、適應症和配藥方式。這些因素促使生產商和經銷商重新評估其生命週期策略，增加對處方醫生的針對性教育投入，並探索既能支持合理用藥又能保持療效的製劑創新。

對美國於 2025 年實施的關稅對頭孢噻呋的供應、採購和貿易動態的累積經濟和營運影響進行詳細評估。

美國2025年加徵的關稅對頭孢噻呋供應鏈產生了多方面的影響，改變了採購成本結構和下游營運計畫。關稅調整增加了從受影響的貿易夥伴處採購某些活性成分和製劑的成本，迫使採購團隊加快重新評估供應商組合併尋找替代貨源。因應措施包括短期戰術性調整，例如改變運輸路線和調整安全存量基準，以及長期策略決策，例如關鍵採購的在地化或區域化。

對動物種類、臨床適應症、給藥途徑、製劑選擇和最終用戶特徵如何影響使用模式進行詳細的細分分析。

細分市場分析揭示了不同動物種類、臨床適應症、給藥途徑、製劑偏好和終端使用者環境在治療用途和商業重點方面的差異。依動物種類分類，市場可分為牛、家禽和豬，其中牛又可細分為牛和牛。每個細分市場都展現出獨特的疾病特徵、給藥方案和經濟接受度，這些因素都會影響產品選擇和給藥策略。依疾病適應症分類，胃腸道感染疾病、呼吸道感染疾病和全身性性行為感染的用藥情況也存在差異，其中呼吸道感染可細分為牛呼吸道疾病、家禽呼吸道疾病和豬呼吸道疾病。這反映了不同物種的病原體流行情況和防治措施的差異。

區域分析整合了主要全球區域的促進因素、法規環境、供應鏈實際情況和臨床需求趨勢。

區域趨勢在頭孢噻呋的監管、供應和推廣中發揮著至關重要的作用，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的模式。在美洲，各國之間存在著顯著的差異，同時各國也努力實現監管協調，這影響著許可期限和處方標準。該地區龐大的商業畜牧業優先考慮生產力和疾病預防，因此對兼顧療效、合規性和消費者合理用藥期望的治療藥物有著強烈的需求。

從企業層級深入分析了safefur供應鏈中的競爭定位、研發重點、夥伴關係關係、商業化策略和業務永續營運。

頭孢噻呋領域的企業競爭格局取決於其自身能力，包括研發、合規性、生產規模和分銷網路。投資於製劑創新（例如濃縮液體製劑和簡化農場管理的即用型製劑）的企業，既能滿足獸醫對便利性和給藥準確性的需求，又能實現差異化競爭優勢。同樣重要的是，企業還需投資於藥品監測、品質系統以及與監管機構的合作，以妥善應對不斷變化的標籤要求和相關法規，確保正確使用。

為行業領導者提供切實可行的建議，以加強供應鏈韌性、促進負責任的使用，並透過夥伴關係提高商業性靈活性。

產業領導者應採取一系列切實可行的措施，以平衡療效、監管責任和供應韌性。首先，企業應投資於關鍵原料和成品的多供應商合格和雙重採購策略，以降低貿易政策變化和物流瓶頸帶來的風險。這項營運緊急時應對計畫應與基於情境的庫存管理政策和合約條款相結合，以便在供應中斷時能夠迅速重新分配供應。

透明的調查方法，說明了原始資料和二手資料的收集、檢驗通訊協定、與專家的諮詢以及分析安全措施。

本分析採用混合研究方法，結合結構化的原始資料和全面的二手數據，並輔以嚴格的檢驗通訊協定。原始數據包括與執業獸醫、供應鏈和監管專家以及行業領袖的專家諮詢，這些專家提供了關於臨床實踐、採購行為和監管合規性的經驗觀點。二手資料包括公開的監管文件、臨床指南和同行評審文獻，用於建立臨床背景並對原始研究結果進行三角驗證。

整合結論，重點強調管理優先事項、持續供應的必要性以及對指導獸藥決策者的實際意義。

本文的研究結果總結了與頭孢噻呋及相關獸藥相關的相關人員應指南的幾項核心挑戰。管理和監管合規是永續使用的不可或缺的基礎。提高診斷準確性和加強處方醫師教育的努力將有助於改善臨床療效並提升聲譽。強調多元化、合約柔軟性和品質保證的供應鏈策略對於降低貿易政策波動和物流不穩定帶來的風險至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：頭孢噻呋市場：路線

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服

第9章：頭孢噻呋市場：依適應症分類

  • 胃腸道感染疾病
  • 呼吸道感染疾病
    • 牛呼吸道疾病
    • 家禽呼吸道疾病
    • 豬的呼吸系統疾病
  • 全身性行為感染

第10章：頭孢噻呋市場以劑型分類

  • 液體
    • 濃縮液
    • 即用型
  • 粉末
  • 預混合料

第11章：塞夫蒂奧弗魯市場：以最終用戶分類

  • 農場
    • 大型農場
    • 小規模農場
  • 零售藥房
  • 動物醫院

第12章：頭孢噻呋市場：依動物類型分類

  • 牛
    • 牛
    • 牛
  • 家禽
  • 豬

第13章：Ceftioful 市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：塞夫蒂歐弗魯市場：依集團分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：頭孢噻呋市場：依國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國頭孢噻呋市場

第17章：中國頭孢菲芙市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd
  • Elanco Animal Health Incorporated
  • Huvepharma EOOD
  • Jiangsu Hengrui Medicine Co., Ltd
  • Lupin Limited
  • Merck & Co., Inc
  • Norbrook Laboratories Ltd
  • Novartis AG
  • Phibro Animal Health Corporation
  • Sanofi SA
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Shenzhen Kangning Pharmaceutical Co., Ltd
  • Sun Pharmaceutical Industries Ltd
  • Vetoquinol SA
  • Virbac SA
  • Zhejiang Hisun Pharmaceutical Co., Ltd
  • Zoetis Inc
Product Code: MRR-1A1A064C0547

The Ceftiofur Market was valued at USD 471.85 million in 2025 and is projected to grow to USD 505.78 million in 2026, with a CAGR of 9.18%, reaching USD 872.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 471.85 million
Estimated Year [2026] USD 505.78 million
Forecast Year [2032] USD 872.82 million
CAGR (%) 9.18%

Comprehensive introduction to ceftiofur's therapeutic role in modern veterinary care, regulatory landscape, stewardship expectations, and stakeholder priorities

Ceftiofur remains a cornerstone antimicrobial in veterinary medicine, valued for its broad-spectrum activity and established clinical utility across multiple livestock species. Its role within therapeutic protocols continues to be shaped by evolving clinical evidence, veterinary practice standards, and an intensifying global focus on antimicrobial stewardship. As stakeholders weigh therapeutic benefits against regulatory and public health obligations, a clear understanding of ceftiofur's clinical indications, routes of administration, and formulation options becomes essential for clinicians, farm managers, and supply chain planners alike.

Regulatory frameworks and stewardship expectations vary by jurisdiction, influencing prescribing behavior and product availability. Concurrently, advances in diagnostic capacity and disease surveillance are accelerating the shift from empiric to targeted therapy in many settings, which affects how ceftiofur is used in practice. Economic pressures on producers and distributors, coupled with heightened scrutiny from consumers and regulators, underscore the need for strategic clarity around procurement, inventory management, and responsible use policies. This introduction sets the stage for a focused analysis that integrates clinical, regulatory, and commercial perspectives to support informed decision-making.

Analysis of transformative shifts reshaping ceftiofur application, supply chains, antimicrobial stewardship, and product innovation in veterinary sectors

The landscape in which ceftiofur is developed, distributed, and prescribed is undergoing substantive change driven by regulatory shifts, supply chain reconfiguration, and technological innovation. Heightened regulatory scrutiny and an increasingly stringent stewardship agenda are reshaping product labeling, permissible indications, and dispensing practices. These forces are prompting manufacturers and distributors to reexamine lifecycle strategies, invest in targeted education for prescribers, and explore formulation innovations that support judicious use while maintaining therapeutic efficacy.

At the same time, supply chain pressures-from raw material sourcing to finished-goods logistics-are driving organizations to diversify suppliers, strengthen inventory controls, and adopt more transparent procurement practices. Advancements in diagnostics, including rapid detection tools and improved laboratory networks, are enabling earlier and more accurate disease identification, which in turn informs more precise antimicrobial selection. Collectively, these shifts are encouraging a transition from volume-based distribution models toward value-based approaches that prioritize outcomes, traceability, and long-term sustainability. Stakeholders that anticipate and adapt to these transformative trends will be better positioned to align clinical needs, regulatory expectations, and commercial resilience.

Detailed evaluation of the cumulative economic and operational impact of United States tariffs enacted in 2025 on ceftiofur supply, sourcing, and trade dynamics

The United States tariffs introduced in 2025 have had a multi-dimensional effect on the ceftiofur supply continuum, altering sourcing economics and downstream operational planning. Tariff adjustments increased landed costs for certain active pharmaceutical ingredients and formulated products originating from affected trade partners, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. This response encompassed both near-term tactical shifts-such as re-routing shipments and adjusting safety stock levels-and longer-term strategic decisions to localize or regionalize critical sourcing.

Pricing pressures were complemented by logistical constraints as some suppliers prioritized markets with fewer trade frictions, thereby creating short windows of constrained availability for distributors and end users. Regulatory compliance and quality-assurance requirements limited the universe of acceptable alternative sources, which added complexity to supplier transitions. In response, many organizations enhanced contract flexibility and invested in scenario planning to maintain supply continuity. The tariff-induced environment also catalyzed conversations about vertical integration and contractual hedging to reduce exposure to future trade policy volatility. As a result, stakeholders are increasingly embedding geopolitical risk assessments into procurement planning and clinical continuity strategies.

In-depth segmentation insights on how animal type, clinical indications, administration routes, formulation choices and end-user profiles shape use patterns

Segmentation analysis illuminates how therapeutic use and commercial priorities diverge across animal types, clinical indications, routes of administration, formulation preferences, and end-user settings. Within animal type, the market is differentiated by Cattle, Poultry, and Swine, with Cattle further subdivided into Beef Cattle and Dairy Cattle; each segment exhibits distinct disease profiles, dosing regimens, and economic tolerances that influence product selection and administration strategies. Disease indication segmentation shows varied use across Gastrointestinal Infections, Respiratory Infections, and Systemic Infections, and the respiratory category is further distinguished by Bovine Respiratory Disease, Poultry Respiratory Disease, and Swine Respiratory Disease, reflecting species-specific pathogen prevalence and management practices.

Route-based segmentation highlights the predominance of Injectable and Oral administration, with the Injectable route further differentiated into Intramuscular, Intravenous, and Subcutaneous approaches that carry implications for dosing accuracy, withdrawal periods, and on-farm administration logistics. Formulation analysis distinguishes Liquid, Powder, and Premix offerings, where Liquid products are further categorized into Concentrate and Ready To Use variants that affect handling, storage, and dosing convenience. End-user segmentation underscores divergent procurement behaviors and usage patterns across Farm, Retail Pharmacies, and Veterinary Clinics, with Farm users split into Large Farms and Small Farms; these distinctions drive preferences for pack sizes, formulation types, and service-level expectations. Together, these segmentation lenses enable a granular understanding of demand drivers and operational constraints, and inform targeted strategies for product development, distribution, and stewardship initiatives.

Regional intelligence that synthesizes drivers, regulatory environments, supply chain realities, and clinical demand trends across major global regions

Regional dynamics play a decisive role in how ceftiofur is regulated, accessed, and deployed, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory harmonization efforts coexist with significant heterogeneity at the national level, influencing licensing timelines and prescribing norms. The region's large commercial livestock sectors emphasize productivity and disease prevention, which results in strong demand for therapeutics that balance efficacy with regulatory compliance and consumer expectations for responsible use.

Europe, Middle East & Africa present a varied regulatory tapestry where stewardship imperatives and consumer-facing transparency demands are especially pronounced in many European markets, while certain EMEA territories are still building diagnostic and distribution infrastructures. Asia-Pacific demonstrates fast-evolving demand patterns driven by rapid intensification of production systems, expanding veterinary services, and increasing regulatory attention to antimicrobial resistance. Across all regions, supply chain resilience, regulatory clarity, and the availability of veterinary expertise are the primary determinants of how ceftiofur is positioned and utilized. Businesses that tailor commercial approaches to regional regulatory climates, distribution realities, and clinical priorities will find better alignment with local stakeholders and greater operational success.

Strategic company-level insights spotlighting competitive positioning, R&D focus, partnerships, commercialization tactics and operational resilience in ceftiofur supply

Competitive dynamics among companies operating in the ceftiofur space are defined by capabilities in R&D, regulatory affairs, manufacturing scale, and distribution reach. Firms that invest in formulation innovation, such as concentrated liquid formats or ready-to-use presentations that simplify on-farm administration, can secure differentiation while addressing practitioner preference for convenience and dosing accuracy. Equally important are investments in pharmacovigilance, quality systems, and regulatory engagement to navigate evolving labeling requirements and stewardship-related restrictions.

Strategic partnerships and contract manufacturing relationships have become critical levers for operational continuity, enabling flexibility in sourcing and capacity scaling. Companies with diversified supply chains and transparent traceability practices have demonstrated greater resilience to trade disruptions and regulatory shifts. Commercially, successful organizations often combine evidence-based education for veterinarians and farm personnel with targeted support services that address withdrawal management, dosing optimization, and stewardship compliance. Those that align their R&D and commercialization strategies with prevailing clinical needs and regulatory expectations are better positioned to retain trust among prescribers and end users while maintaining operational stability.

Actionable recommendations for industry leaders to strengthen supply chain resilience, promote responsible use, and enhance commercial agility through partnerships

Industry leaders should adopt a pragmatic set of actions to balance therapeutic effectiveness with regulatory responsibility and supply resilience. First, firms should invest in multi-source qualification and dual-sourcing strategies for critical inputs and finished products to reduce vulnerability to trade policy changes and logistical bottlenecks. This operational contingency planning should be paired with scenario-based inventory policies and contractual terms that permit rapid reallocation of supply when disruptions occur.

Second, strengthening stewardship requires coordinated investment in diagnostics, practitioner education, and data capture to enable targeted therapy and to demonstrate responsible use. Third, formulation and route optimization-including exploration of ready-to-use liquid presentations and administration protocols that lower the risk of dosing errors-can improve adherence and reduce inadvertent selection pressure. Fourth, commercial strategies should prioritize transparent engagement with regulators, veterinarians, and farm operators to align on labeling, withdrawal guidance, and usage monitoring. Finally, leaders should pursue partnerships that enhance distribution agility and invest in analytics that convert operational data into actionable intelligence for procurement, pharmacovigilance, and clinical outcomes tracking. Together these actions create a pragmatic roadmap for operational and clinical resilience.

Transparent research methodology describing primary and secondary data collection, validation protocols, expert consultation, and analytic safeguards

This analysis is grounded in a mixed-methods research approach that combines structured primary research with comprehensive secondary review and rigorous validation protocols. Primary inputs include expert consultations with practicing veterinarians, supply chain and regulatory specialists, and commercial leaders, all of whom provide grounded perspectives on clinical practice, procurement behavior, and regulatory compliance. Secondary inputs consist of publicly available regulatory documents, clinical guidelines, and peer-reviewed literature used to establish clinical context and to triangulate primary findings.

Data validation was achieved through cross-verification of supplier and regulatory information across multiple sources, and by reconciling practitioner-reported behaviors with documented industry trends. Analytical methods included thematic synthesis for qualitative inputs and scenario analysis for supply chain and policy-driven impacts. Limitations are acknowledged, including variability in regional data transparency and the evolving nature of regulatory guidance; where appropriate, assumptions are explicitly stated and sensitivity considerations are applied. The methodology emphasizes transparency and reproducibility to ensure that conclusions are robust and relevant for decision-makers.

Concluding synthesis highlighting stewardship priorities, supply continuity imperatives, and practical implications to guide decision-makers in veterinary therapeutics

The cumulative insights presented here converge on several core imperatives that should guide stakeholders engaged with ceftiofur and related veterinary therapeutics. Stewardship and regulatory alignment are non-negotiable foundations for sustainable use; efforts to improve diagnostic precision and to educate prescribers will yield dividends in both clinical outcomes and reputational resilience. Supply chain strategies that emphasize diversification, contractual flexibility, and quality assurance are essential to mitigate exposure to trade policy shifts and logistical volatility.

Commercial success will increasingly depend on the ability to tailor product offerings and service models to differentiated end-user needs, whether those are large integrated farms seeking scalable solutions or smaller operations that require more hands-on support. Companies that invest in responsible-use messaging, transparent traceability, and collaborative partnerships with veterinary stakeholders will be best placed to navigate evolving regulatory landscapes and to sustain clinical relevance. The synthesis underscores the importance of integrating clinical, operational, and commercial perspectives to drive pragmatic, evidence-based decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ceftiofur Market, by Route

  • 8.1. Injectable
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
  • 8.2. Oral

9. Ceftiofur Market, by Indication

  • 9.1. Gastrointestinal Infections
  • 9.2. Respiratory Infections
    • 9.2.1. Bovine Respiratory Disease
    • 9.2.2. Poultry Respiratory Disease
    • 9.2.3. Swine Respiratory Disease
  • 9.3. Systemic Infections

10. Ceftiofur Market, by Formulation

  • 10.1. Liquid
    • 10.1.1. Concentrate
    • 10.1.2. Ready To Use
  • 10.2. Powder
  • 10.3. Premix

11. Ceftiofur Market, by End User

  • 11.1. Farm
    • 11.1.1. Large Farms
    • 11.1.2. Small Farms
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics

12. Ceftiofur Market, by Animal Type

  • 12.1. Cattle
    • 12.1.1. Beef Cattle
    • 12.1.2. Dairy Cattle
  • 12.2. Poultry
  • 12.3. Swine

13. Ceftiofur Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ceftiofur Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ceftiofur Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ceftiofur Market

17. China Ceftiofur Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aurobindo Pharma Limited
  • 18.6. Bayer AG
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Ceva Sante Animale
  • 18.9. Chongqing Huapont Pharmaceutical Co., Ltd
  • 18.10. Cipla Limited
  • 18.11. Dechra Pharmaceuticals PLC
  • 18.12. Dr. Reddy's Laboratories Ltd
  • 18.13. Elanco Animal Health Incorporated
  • 18.14. Huvepharma EOOD
  • 18.15. Jiangsu Hengrui Medicine Co., Ltd
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc
  • 18.18. Norbrook Laboratories Ltd
  • 18.19. Novartis AG
  • 18.20. Phibro Animal Health Corporation
  • 18.21. Sanofi S.A.
  • 18.22. Shandong Lukang Pharmaceutical Co., Ltd
  • 18.23. Shanghai Pharmaceuticals Holding Co., Ltd
  • 18.24. Shenzhen Kangning Pharmaceutical Co., Ltd
  • 18.25. Sun Pharmaceutical Industries Ltd
  • 18.26. Vetoquinol SA
  • 18.27. Virbac S.A.
  • 18.28. Zhejiang Hisun Pharmaceutical Co., Ltd
  • 18.29. Zoetis Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEFTIOFUR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CEFTIOFUR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CEFTIOFUR MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CEFTIOFUR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEFTIOFUR MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CEFTIOFUR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CEFTIOFUR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEFTIOFUR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CEFTIOFUR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CEFTIOFUR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CEFTIOFUR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CEFTIOFUR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)